![Peter Neubeck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Neubeck
Vorsitzender bei Emergence Therapeutics AG
Ursprung des Netzwerks ersten Grades von Peter Neubeck
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
TVM Capital GmbH
![]() TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.
27
| Private Company | Investment Managers | 27 |
Kurma Partners SA
![]() Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.
14
| Holding Company | Investment Managers | 14 |
TACALYX GmbH
![]() TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Emergence Therapeutics AG
![]() Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.
7
| Subsidiary | Pharmaceuticals: Major | 7 |
Synendos Therapeutics AG
![]() Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland.
6
| Holding Company | Medical Specialties | 6 |
Kurma Partners /DE/
1
| Subsidiary | Investment Managers | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Peter Neubeck
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
INSEAD | College/University | Doctorate Degree Masters Business Admin Masters Business Admin Masters Business Admin | |
ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
BliNK Biomedical SAS
![]() BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Biotechnology | Director/Board Member Chief Executive Officer Chief Executive Officer | |
VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Graduate Degree Undergraduate Degree | |
TXCELL | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
CEVEC Pharmaceuticals GmbH
![]() CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AYOXXA Biosystems GmbH
![]() AYOXXA Biosystems GmbH BiotechnologyHealth Technology AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member Director/Board Member | |
NOXXON Pharma AG
![]() NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Chairman Chairman | |
Tel-Aviv University
![]() Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Graduate Degree Undergraduate Degree | |
Pharvaris GmbH
![]() Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder Director/Board Member | |
INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Chairman | |
University of Duisburg-Essen | College/University | Doctorate Degree Doctorate Degree | |
Ambu Innovation GmbH
![]() Ambu Innovation GmbH Medical SpecialtiesHealth Technology Ambu Innovation GmbH engages in the development and distribution of single-use and light-weight robotically-assisted high definition endoscopy products in the field of gastroenterology and gastro-intestinal surgery. Its products include invendoscope SC210, invendo ScopeController, and invendo SPU E210. The company was founded in 1992 and is headquartered in Kissing, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
Definiens AG
![]() Definiens AG Packaged SoftwareTechnology Services Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany. | Packaged Software | Director/Board Member Director/Board Member | |
iTAC Software AG
![]() iTAC Software AG Packaged SoftwareTechnology Services iTAC Software AG provides software solutions. It offers serves the automotive industry, medical technologies, metal processing industry, energy and utilities industry, and electronics industry. The firm's products are manufacturing execution system (MES) suite, embedded systems, smart devices and enterprise framework. The company was founded by Dieter Meuser, Volker Burch and Christine Lahnstein in 1998 and is headquartered in Montabaur, Germany. | Packaged Software | Chairman Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
![]() Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
INTEGRAGEN | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Eurazeo Investment Manager - EIM SA
![]() Eurazeo Investment Manager - EIM SA Investment ManagersFinance Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA. | Investment Managers | Investment Committee Member Private Equity Investor | |
PHARVARIS N.V. | Pharmaceuticals: Major | Founder Director/Board Member | |
Shire Orphan Therapies GmbH
![]() Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Argobio SAS
![]() Argobio SAS Miscellaneous Commercial ServicesCommercial Services Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research. | Miscellaneous Commercial Services | President Chairman | |
Amolyt Pharma SAS
![]() Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
SAFE ORTHOPAEDICS SA | Medical Specialties | Director/Board Member Director/Board Member | |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree | |
Creathor Venture Management GmbH
![]() Creathor Venture Management GmbH Investment ManagersFinance Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions. | Investment Managers | Private Equity Investor Private Equity Investor | |
Seventure Partners SA
![]() Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris. | Investment Managers | Private Equity Investor Private Equity Investor | |
Philipps University of Marburg | College/University | Doctorate Degree Undergraduate Degree | |
Freie Universität Berlin | College/University | Undergraduate Degree Corporate Officer/Principal | |
Cryotherapeutics SA
![]() Cryotherapeutics SA Medical SpecialtiesHealth Technology Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
Nuevolution A/S
![]() Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
SuppreMol GmbH
![]() SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
High-Tech Gründerfonds Management GmbH
![]() High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Analyst Private Equity Investor | |
DIREVO Industrial Biotechnology GmbH
![]() DIREVO Industrial Biotechnology GmbH Miscellaneous Commercial ServicesCommercial Services DIREVO Industrial Biotechnology GmbH provides bioengineering services for industrial, molecular biology, and reaction chemistry applications. It offers enzyme and strain engineering, application development, and process engineering services. The firm also offers research and development services for bio-fuel production. The company was founded in July 2008 and is headquartered in Cologne, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
leon-nanodrugs GmbH
![]() leon-nanodrugs GmbH Pharmaceuticals: MajorHealth Technology leon-nanodrugs GmbH develops oral and parenteral drugs. The firm's services include nanotechnology in medicine, MJR technology, pipeline, partnering with leon and leon network. The company was founded by Wolfgang Beier and Cornelia Beier in 2011 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member | |
STAT-Dx Life SL
![]() STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
TVM Life Science Management GmbH
![]() TVM Life Science Management GmbH Miscellaneous Commercial ServicesCommercial Services Part of TVM Capital GmbH, TVM Life Science Management GmbH provides management services. The company is based in Munich, Germany. The CEO of the German company is Stefan Fischer. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Executive Officer | |
THERADIAG | Medical Specialties | Director/Board Member Director/Board Member | |
Step Pharma SAS
![]() Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Director/Board Member |
Statistik
International
Deutschland | 23 |
Frankreich | 17 |
Schweiz | 3 |
Niederlande | 3 |
Dänemark | 3 |
Sektoral
Health Technology | 25 |
Consumer Services | 8 |
Commercial Services | 7 |
Finance | 7 |
Technology Services | 4 |
Operativ
Director/Board Member | 311 |
Corporate Officer/Principal | 64 |
Chairman | 62 |
Private Equity Investor | 58 |
Chief Executive Officer | 36 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Philippe Peltier | 45 |
Søren Lemonius | 39 |
Rémi Droller | 29 |
Helmut Schühsler | 28 |
Hubert Birner | 27 |
Marios Fotiadis | 25 |
Anthony Adam Rosenberg | 23 |
Laurent Arthaud | 21 |
Thierry Laugel | 18 |
Aristotelis Nastos | 17 |
Klaus Schollmeier | 17 |
Christoph Schröder | 14 |
Irina Staatz-Granzer | 14 |
Alexandra Goll | 14 |
Matthew Hammond | 13 |
- Börse
- Insiders
- Peter Neubeck
- Unternehmensverbindungen